title: Reply to Kaasch et al.
authors.affiliation: Infectious Diseases Service.
authors.forename: Carlos
authors.initials: C
authors.lastname: Cervera
authors.affiliation: Experimental Endocarditis Research Laboratory, Hospital Clinic-IDIBAPS, University of Barcelona, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Garcia de la Maria
authors.affiliation: Infectious Diseases Service.
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Pericas
authors.affiliation: Infectious Diseases Service.
authors.forename: Asunción
authors.initials: A
authors.lastname: Moreno
authors.affiliation: Infectious Diseases Service.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Miro
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003023:Cloxacillin / Q000494:pharmacology*; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D003023:Cloxacillin